of solvents.

46. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 10 in a pharmaceutically acceptable solvent or mixture of solvents.

47. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 11 in a pharmaceutically acceptable solvent or mixture of solvents.

48. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 12 in a pharmaceutically acceptable solvent or mixture of solvents.

49. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 13 in a pharmaceutically acceptable solvent or mixture of solvents.

50. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 14 in a pharmaceutically acceptable solvent or mixture of solvents.

51. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 15 in a pharmaceutically acceptable solvent or mixture of solvents.

52. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 16 in a pharmaceutically acceptable solvent or mixture of solvents.

53. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 17 in a pharmaceutically acceptable solvent or mixture of solvents.

54. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving a compound of Claim 18 in a pharmaceutically acceptable solvent or mixture of solvents.

55. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of

Claim 1 or (b) a pharmaceutical composition comprising a compound of Claim 1 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

56. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 2 or (b) a pharmaceutical composition comprising a compound of Claim 2 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

57. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 3 or (b) a pharmaceutical composition comprising a compound of Claim 3 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

58. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 4 or (b) a pharmaceutical composition comprising a compound of Claim 4 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

59. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 5 or (b) a pharmaceutical composition comprising a compound of Claim 5 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

60. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 6 or (b) a pharmaceutical composition comprising a compound of Claim 6 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

61. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 7 or (b) a pharmaceutical composition comprising a compound of Claim 7 and

one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

62. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 8 or (b) a pharmaceutical composition comprising a compound of Claim 8 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

63. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 9 or (b) a pharmaceutical composition comprising a compound of Claim 9 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

64. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 10 or (b) a pharmaceutical composition comprising a compound of Claim 10 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

65. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 11 or (b) a pharmaceutical composition comprising a compound of Claim 11 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

66. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 12 or (b) a pharmaceutical composition comprising a compound of Claim 12 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

67. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 13 or (b) a pharmaceutical composition comprising a compound of Claim 13 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

68. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 14 or (b) a pharmaceutical composition comprising a compound of Claim 14 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

69. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 15 or (b) a pharmaceutical composition comprising a compound of Claim 15 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

70. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 16 or (b) a pharmaceutical composition comprising a compound of Claim 16 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

71. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 17 or (b) a pharmaceutical composition comprising a compound of Claim 17 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

72. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease~~ Use of a therapeutically effective amount of (a) a compound of Claim 18 or (b) a pharmaceutical composition comprising a compound of Claim 18 and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

73. The ~~method~~ use of Claim 55, wherein the compound or pharmaceutical composition is administered by an oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, otic, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular route.

74. The ~~method~~ use of Claim 55, wherein the disease is a neoplastic, immune, or autoimmune disease.

75. The ~~method~~ use of Claim 74, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

76. The ~~method~~ use of Claim 74, wherein the neoplastic disease is a lymphoid malignancy.

77. The ~~method~~ use of Claim 76, wherein the lymphoid malignancy is non-Hodgkin's lymphoma, chronic lymphoid leukemia, or acute lymphocytic leukemia.

78. The ~~method~~ use of Claim 55, wherein the therapeutically effective amount is administered orally in a dose of about 50 to about 1000 mg Compound 1 per day at an average treatment interval of about 3 hours to about 7 days.

79. The ~~method~~ use of Claim 55, wherein the therapeutically effective amount is administered orally once daily in a dose of about 200 to about 400 mg Compound 1 free base equivalent per day.

80. ~~A method for treating a disease characterized by apoptotic dysfunction and/~~

~~or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 1 ~~to a subject having the disease~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

81. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 2 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

82. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 3 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

83. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 4 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

84. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 5 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

85. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 6 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

86. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 7 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

87. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 8 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

88. ~~A method for treating a disease characterized by apoptotic dysfunction and/or~~

~~overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 9 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

89. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 10 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

90. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 11 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein~~.~~

91. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 12 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

92. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 13 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

93. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 14 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

94. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 15 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

95. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 16 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

96. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 17 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

97. ~~A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering~~ Use of a solution or dispersion of a compound of Claim 18 in a pharmaceutically acceptable solvent or mixture of solvents ~~to a subject having the disease,~~ in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

98. The ~~method~~ use of ~~Claim~~ claim 80, wherein the solution is administered by an oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, otic, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular route.

99. The ~~method~~ use of ~~Claim~~ claim 80, wherein the disease is a neoplastic, immune, or autoimmune disease.

100. The ~~method~~ use of ~~Claim~~ claim 99, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary

adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

101. The ~~method~~ use of ~~Claim~~ claim 99, wherein the neoplastic disease is a lymphoid malignancy.

102. The ~~method~~ use of ~~Claim~~ claim 101, wherein the lymphoid malignancy is non-Hodgkin's lymphoma, chronic lymphoid leukemia, or acute lymphocytic leukemia.

103. The ~~method~~ use of ~~Claim~~ claim 80, wherein the solution is to be administered orally in a dose of about 50 to about 1000 mg Compound 1 per day at an average treatment interval of about 3 hours to about 7 days.

104. The ~~method~~ use of ~~Claim~~ claim 80, wherein the solution is to be administered orally once daily in a dose of about 200 to about 400 mg Compound 1 free base equivalent per day.

105. Compound 1 hydrochloride.

106. Compound 1 sulfate.